Creo Medical Group (LON:CREO) Earns House Stock Rating from Shore Capital Group

Creo Medical Group (LON:CREO)‘s stock had its “house stock” rating restated by stock analysts at Shore Capital Group in a research report issued on Tuesday,Digital Look reports. They currently have a GBX 40 price target on the stock. Shore Capital Group’s price objective points to a potential upside of 171.19% from the stock’s current price.

Creo Medical Group Stock Up 1.7%

Creo Medical Group stock opened at GBX 14.75 on Tuesday. The business has a fifty day moving average of GBX 12.10 and a two-hundred day moving average of GBX 12.20. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. The firm has a market cap of £60.84 million, a P/E ratio of -14.75 and a beta of 1.62. Creo Medical Group has a twelve month low of GBX 9.52 and a twelve month high of GBX 18.50.

Creo Medical Group (LON:CREO) last posted its earnings results on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. The company had revenue of GBX 600 million for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. On average, analysts forecast that Creo Medical Group will post -10.0800005 earnings per share for the current fiscal year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.